Ipragliflozin

Ipragliflozin
Haworth projection (bottom)
Clinical data
Trade namesSuglat
Other names(1S)-1,5-anhydro-1-C-{3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl}-D-glucitol
Routes of
administration		By mouth (tablets)
ATC code
Legal status
Legal status
  • US: Not available
  • Rx-only (JP)
Pharmacokinetic data
Bioavailability90.2%
Protein binding94.6–96.5%
MetabolismUGT2B7 (major), UGT2B4, 1A8, 1A9 (minor)
Elimination half-life14.97±4.58 hours
ExcretionUrine (67.9%), feces (32.7%)[1]
Identifiers
  • (1S)-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H21FO5S
Molar mass404.45 g·mol−1
3D model (JSmol)
  • S1C(=CC2=C1C=CC=C2)CC=2C=C(C=CC2F)[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO
  • InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1 COPY
  • Key:AHFWIQIYAXSLBA-RQXATKFSSA-N

Ipragliflozin (INN,[2]: 69  trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014,[3] and in Russia on May 22, 2019.[4]

Ipragliflozin is a Sodium/glucose cotransporter 2 (SGLT2) inhibitor (gliflozin).[5] These membrane proteins are on the cell surface and transfer glucose into the cells. SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys. Ipragliflozin reduces blood glucose levels by inhibiting the reuptake of glucose by selectively inhibiting SGLT2.[6]

  1. ^ "Suglat (ipragliflozin L-proline) Tablets 25 mg, 50 mg. Prescribing Information" (PDF) (in Japanese). Astellas. Archived from the original (PDF) on 16 November 2016. Retrieved 15 November 2016.
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization.
  3. ^ "Approval of Suglat Tablets, a Selective SGLT2 Inhibitor for Treatment of Type 2 Diabetes, in Japan" (PDF). Astellas Pharma Inc. Archived from the original (PDF) on 16 April 2015. Retrieved 15 November 2016.
  4. ^ "Suglat (ipragliflozin) Film-coated Tablets". Russian State Register of Medicines (in Russian). Astellas Pharma Europe B.V. Retrieved 9 November 2019.
  5. ^ Takasu T, Takakura S, Kaku S (January 2015). "[Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica. 145 (1): 36–42. doi:10.1254/fpj.145.36. PMID 25743234.
  6. ^ "Changing Tomorrow" (PDF). Astellas Pharma Inc. 31 March 2014. Archived from the original (PDF) on 4 September 2019. Retrieved 12 November 2016.